Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07227415 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

StatusRecruiting
PhasePhase 1/2
SponsorPfizer
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 162 → 183 locations
  2. Trial sites expanded: 128 → 162 locations Interventions modified · Trial arms changed: 3 → 4 · Eligibility criteria expanded, about 18 words Show 3 more changesShow less
    • Interventions modified
    • Trial arms changed: 3 → 4
    • Eligibility criteria expanded, about 18 words
  3. Trial sites expanded: 109 → 128 locationsv8
  4. Trial sites expanded: 88 → 109 locationsv7
  5. Trial sites expanded: 49 → 88 locations Start date: Mar 12, 2026 to Feb 10, 2026 · Interventions: Combination 1 (Drug), Combination 2 (Drug), PF-08634404 (Biological) to Axitinib (Drug), Ipilimumab (Drug), PF-08634404 (Drug) · Eligibility criteria expanded, about 12 wordsv6 Show 3 more changesShow less
    • Start date: Mar 12, 2026 to Feb 10, 2026
    • Interventions: Combination 1 (Drug), Combination 2 (Drug), PF-08634404 (Biological) to Axitinib (Drug), Ipilimumab (Drug), PF-08634404 (Drug)
    • Eligibility criteria expanded, about 12 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 47 to 49v5
  7. Trial sites expanded: 14 → 46 locationsv4
  8. Start date: Feb 10, 2026 to Mar 12, 2026 Study sites: 14 to 46 · Eligibility criteria revised · Study title expanded, about 1 wordv3 Show 3 more changesShow less
    • Study sites: 14 to 46
    • Eligibility criteria revised
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  9. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 14 · Start date changed from estimate of Dec 4, 2025 to Feb 10, 2026v2 Show 2 more changesShow less
    • Study sites: 0 to 14
    • Start date changed from estimate of Dec 4, 2025 to Feb 10, 2026
  10. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
433 trials monitored
See 31 trials at risk
Kidney Cancer
772 trials monitored
See 53 trials at risk
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.
Trial Details
NCT Number NCT07227415
Lead Sponsor Pfizer
Conditions Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis +5 more
Enrollment 224 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov